Malaysia’s BiotechCorp To Expand Health Care Work
This article was originally published in PharmAsia News
Malaysian Biotechnology says it plans to expand its development capabilities to help it focus on health care biotechnology in addition to agricultural and industrial biotech work. BiotechCorp is funded by the Malaysian government to ensure a place for the country in biotech efforts. The expansion effort includes acquisition of technology platforms to allow the firm to step up development in each of its focus areas. The platforms are to be acquired by the end of the year, CEO Datuk Iskandar Mizal Mahmood said. (Click here for more
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.